

## Drugs for Type 2 Diabetes

(last modified October 2023)

The table below summarizes the agents available for the treatment of type 2 diabetes, including expected A1c reduction when added to metformin, cost, adverse effects, and other pertinent information (e.g., place in therapy, pediatric use, cardiorenal benefit). For additional details on cardiovascular benefits associated with drugs for type 2 diabetes, see our chart, *Diabetes Medications: Cardiovascular and Kidney Impact*.

Expected A1c Reduction <sup>b</sup> /MOA	Maximum Daily Dose <sup>2,24,42</sup> (Cost/30 Days) <sup>a</sup>	Notable Adverse Effects	Comments
<b>Alpha-glucosidase inhibitors:</b> acarbose and miglitol (US)			
0.7% to 0.8% (acarbose, when added to metformin) <sup>1</sup> ~0.3% to 0.8% (miglitol, as monotherapy) <sup>3</sup> MOA: slows intestinal carbohydrate digestion/absorption. <sup>2</sup>	<b>Acarbose</b> 300 mg, divided TID (US: ~\$50)(Canada: \$30.84)  <b>Miglitol</b> 300 mg, divided TID (US: ~\$280)	<ul style="list-style-type: none"> <li>GI (e.g., abdominal pain, flatulence, diarrhea).<sup>1,2</sup></li> <li>Relatively low risk of hypoglycemia.<sup>1</sup></li> </ul>	<ul style="list-style-type: none"> <li>Weight neutral.<sup>1</sup></li> <li>Taken at the start of each main meal.<sup>2</sup></li> <li>Reduces postprandial glucose.<sup>6</sup></li> <li>Beneficial in the treatment of prediabetes (acarbose).<sup>5,7</sup></li> </ul>
<b>Amylin analog:</b> pramlintide (US)( <i>Symlin</i> )			
0.3% to 0.4% (when added to insulin with or without metformin and/or a sulfonylurea) <sup>4,40</sup>  MOA: slows gastric emptying, causes satiety, and reduces postprandial glucagon secretion. <sup>2</sup>	<b>Pramlintide</b> 120 mcg/dose (usually 360 mcg/day; divided, prior to major meals) (~\$2,390)	<ul style="list-style-type: none"> <li>GI (e.g., nausea, vomiting).<sup>2</sup></li> <li>Hypoglycemia can occur if used with insulin. Reduce mealtime insulin dose to reduce risk.<sup>2</sup></li> </ul>	<ul style="list-style-type: none"> <li>Weight loss (~1 kg).<sup>4</sup></li> <li>Injectable.<sup>2</sup></li> <li>Taken immediately before each main meal.<sup>2</sup></li> <li>Reduces postprandial glucose.<sup>8</sup></li> </ul>

Expected A1c Reduction <sup>b</sup> /MOA	Maximum Daily Dose <sup>2,24,42</sup> (Cost/30 Days) <sup>a</sup>	Notable Adverse Effects	Comments
<b>Biguanide:</b> metformin ( <i>Fortamet</i> (US), <i>Glucophage</i> (Canada), <i>Glumetza</i> , generics). Available in combination with alogliptin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin (US), glipizide (US), glyburide (US), linagliptin, pioglitazone (US), saxagliptin, and sitagliptin. See specific agents.			
<p>1% (as monotherapy)<sup>1</sup></p> <p>MOA: inhibits glucose production and absorption; increases insulin sensitivity in muscle and fat.<sup>2</sup></p>	<p><b>Metformin</b> 2,000 to 2,550 mg,* divided BID to TID (US: &lt;\$10)(Canada: &lt;\$10)</p> <p><b>Metformin XR/ER</b> 2,000 mg, once daily or divided BID (US: &lt;\$20)(Canada: \$76.40)</p> <p>*max dose 2,000 mg for 10 to 17 years of age.<sup>2</sup></p>	<ul style="list-style-type: none"> <li>GI (e.g., diarrhea, nausea, abdominal discomfort).<sup>1,2,4</sup> Address with slow titration, of an extended-release formulation taken with food.<sup>4</sup></li> <li>Low risk of hypoglycemia when used as monotherapy.<sup>4</sup></li> <li>Lactic acidosis (very rare) in patients with unstable heart failure, severe kidney impairment, or liver impairment.<sup>4,9,11</sup></li> <li>B12 deficiency. Consider periodic testing.<sup>4,27</sup></li> </ul>	<ul style="list-style-type: none"> <li>First-line with diet and exercise for <b>glucose control</b> (but not for cardiorenal risk-reduction), for prediabetes (adults), and for youth ≥10 years of age.<sup>4,7,27</sup></li> <li>Available as an oral solution (US).</li> <li>Weight neutral to modest weight loss.<sup>4</sup></li> <li>Ameliorates insulin weight gain.<sup>10</sup></li> <li>May reduce CV events and mortality.</li> <li>Safe in patients with stable heart failure and moderate kidney impairment:<sup>4,9</sup> <ul style="list-style-type: none"> <li>Can be initiated in patients with an eGFR &gt;45 mL/min/1.73m<sup>2</sup>. (Canada: ≥30 mL/min/1.73m<sup>2</sup>)<sup>1,12</sup></li> <li>Discontinue if eGFR falls below 30 mL/min/1.73m<sup>2</sup>.<sup>12</sup></li> </ul> </li> </ul>
<p><b>Dipeptidyl peptidase-4 (DPP-4) inhibitor (“gliptins”) or incretin enhancer:</b></p> <ul style="list-style-type: none"> <li>alogliptin (<i>Nesina</i>; with metformin [<i>Kazano</i>]; with pioglitazone [<i>Oseni</i> (US)]; authorized generics [US])</li> <li>linagliptin (<i>Trajenta</i> [US]; <i>Trajenta</i> [Canada]; with metformin [<i>Jentaducto</i>, <i>Jentaducto XR</i> (US)]; with empagliflozin [<i>Glyxambi</i> (US)]; with metformin and empagliflozin [<i>Trijardy XR</i> (US)])</li> <li>saxagliptin (<i>Onglyza</i>, generics [Canada]; with metformin [<i>Kombiglyze</i> (Canada), <i>Kombiglyze XR</i> (US)]; with dapagliflozin [<i>Qtern</i> (US)])</li> <li>sitagliptin (<i>Januvia</i>; with metformin [<i>Janumet</i>, <i>Janumet XR</i>]; with ertugliflozin [<i>Steglujan</i> (US)])</li> </ul>			
<p>0.5% to 0.7%<sup>1</sup></p> <p>MOA: increases insulin secretion in response to elevated blood glucose, decreases glucagon secretion, and slows gastric emptying.<sup>1</sup></p>	<p><b>Alogliptin</b> 25 mg once daily (US: \$195)(Canada: \$71.28)</p> <p><b>Linagliptin</b> 5 mg once daily (US: \$525.08)(Canada: \$77.06)</p> <p><b>Saxagliptin</b> 5 mg once daily (US: \$485.08)(Canada: \$49.23)</p> <p><b>Sitagliptin</b> 100 mg once daily (US: \$547.20)(Canada: \$90.30)</p>	<ul style="list-style-type: none"> <li>Generally well tolerated.<sup>14</sup></li> <li>Low risk of hypoglycemia when used as monotherapy.<sup>4</sup></li> <li>Weight neutral.<sup>7</sup></li> <li>Rare cases of pancreatitis.<sup>1</sup></li> <li>New or worsening heart failure (saxagliptin and alogliptin).<sup>7</sup></li> <li>Rare cases of severe joint pain.<sup>1</sup></li> </ul>	<ul style="list-style-type: none"> <li>Not first-line. Alternative for glycemic control in patients with hypoglycemia risk or overweight/obesity.<sup>7</sup> Reduces postprandial glucose.<sup>13</sup></li> <li>Have not been effective in youth.<sup>27,43</sup></li> <li>Discontinue when more complex insulin regimens (e.g., basal plus prandial insulins) are started.<sup>4</sup></li> <li>Dosage modification with kidney impairment needed (alogliptin, saxagliptin, sitagliptin).<sup>2</sup></li> <li>CYP3A4 interactions (linagliptin, saxagliptin).<sup>2</sup></li> </ul>

Expected A1c Reduction <sup>b</sup> /MOA	Maximum Daily Dose <sup>2,24,42</sup> (Cost/30 Days) <sup>a</sup>	Notable Adverse Effects	Comments
<b>Glucagon-like, peptide-1 (GLP-1) agonist or incretin mimetic:</b> <ul style="list-style-type: none"> <li>dulaglutide (<i>Trulicity</i>)</li> <li>exenatide (<i>Byetta</i> [US]) and exenatide extended release (<i>Bydureon BCise</i> [US])</li> <li>liraglutide (<i>Victoza</i>; with insulin degludec [<i>Xultophy</i>])</li> <li>lixisenatide (<i>Adlyxin</i> [US]; <i>Adlyxine</i> [Canada]; with insulin glargine [<i>Soliqua</i>])</li> <li>semaglutide (<i>Ozempic</i>, <i>Rybelsus</i>)</li> </ul>			
<p>Dulaglutide 1.8%<sup>33</sup></p> <p>Exenatide 0.96%<sup>32</sup></p> <p>Exenatide extended release 1.5% adults;<sup>34</sup> 0.36% pediatrics<sup>35</sup></p> <p>Liraglutide ~1.6% adults;<sup>32</sup> 0.5% pediatrics<sup>36</sup></p> <p>Lixisenatide ~1%<sup>32</sup></p> <p>Semaglutide 2.3% (metformin +/- sulfonyleureas)<sup>38</sup></p> <p>Semaglutide, oral (plus metformin or SGLT2 inhibitor) 1.2%<sup>32</sup></p> <p>MOA: increases insulin secretion in response to elevated blood glucose, decreases glucagon secretion, slows gastric emptying.<sup>1</sup></p>	<p><b>Dulaglutide</b> 4.5 mg once weekly (US: \$930.88)(Canada: \$233.68 [1.5 mg once weekly])</p> <p><b>Exenatide</b> 10 mcg twice daily (US: \$825.19)</p> <p><b>Exenatide extended release</b> 2 mg once weekly (US: \$803.35)</p> <p><b>Liraglutide</b> 1.8 mg once daily (US: ~\$1,117)(Canada: \$325.05)</p> <p><b>Lixisenatide</b> 20 mcg once daily (US: NA)(Canada: \$131.87)</p> <p><b>Semaglutide</b> 2 mg once weekly (US: \$935.77)(Canada: \$227.74 [1 mg once weekly])</p> <p><b>Semaglutide, oral</b> 14 mg once daily (US: \$935.77)(Canada: \$233.38)</p>	<ul style="list-style-type: none"> <li>GI (e.g., diarrhea, nausea, vomiting).<sup>10</sup></li> <li>Low risk of hypoglycemia when used as monotherapy.<sup>4</sup></li> <li>Unclear association with acute pancreatitis.<sup>15</sup></li> <li>Low risk of gallbladder disease.<sup>16</sup></li> <li>May lead to retinopathy complications.<sup>1</sup></li> <li>Linked to pancreatic and medullary thyroid cancer in rats.<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>First-line for CV disease or high CV risk (dulaglutide, liraglutide, semaglutide [injection]).<sup>7</sup></li> <li>Add-on to metformin and/or insulin in youth ≥10 years of age (liraglutide, once-weekly exenatide).<sup>35,44</sup></li> <li>In adults who need “higher glycemic efficacy,” generally start with a GLP-1 agonist, then add basal insulin.<sup>4</sup></li> <li>Weight loss (up to 14 pounds [6.4 kg] with semaglutide injection).<sup>38</sup></li> <li>All are injectable, but an oral formulation of semaglutide is available.</li> <li>Avoid if eGFR &lt;45 mL/min/1.73m<sup>2</sup> (extended-release exenatide), &lt;30 mL/min/1.73m<sup>2</sup> (immediate-release exenatide), or &lt;15 mL/min/1.73m<sup>2</sup> (lixisenatide).<sup>2</sup></li> <li>Reduces postprandial glucose.<sup>13</sup></li> <li>CV benefit (dulaglutide, liraglutide, semaglutide [injection]).</li> <li>Kidney benefit (except exenatide [unknown]).</li> </ul>

Expected A1c Reduction <sup>b</sup> /MOA	Maximum Daily Dose <sup>2,24,42</sup> (Cost/30 Days) <sup>a</sup>	Notable Adverse Effects	Comments
<b>Glucagon-like, peptide-1 (GLP-1) agonist and glucose-dependent insulinotropic polypeptide (GIP) agonist (a “twincretin”):</b> • tirzepatide ( <i>Mounjaro</i> )			
2.3% <sup>31</sup>  MOA: increases insulin sensitivity, increases insulin secretion in response to elevated glucose, decreases glucagon secretion, slows gastric emptying. <sup>31,37</sup>	<b>Tirzepatide</b> 15 mg once weekly (US: \$1,023.04)(Canada: NA)	<ul style="list-style-type: none"> <li>• GI (e.g., diarrhea, nausea, vomiting).<sup>31,37</sup></li> <li>• Low risk of hypoglycemia when used as monotherapy.<sup>4</sup></li> <li>• Pancreatitis rarely reported in clinical trials (23 events per 10,000 years of exposure [~twice the placebo rate]).<sup>31,37</sup></li> <li>• Low risk of gallbladder disease in clinical trials (0.6% vs 0% placebo).<sup>31,37</sup></li> <li>• Linked to medullary thyroid cancer in rats.<sup>31,37</sup></li> </ul>	<ul style="list-style-type: none"> <li>• More weight loss than GLP-1 agonists (up to 25 pounds [11.2 kg] with maximum dose in patients with type 2 diabetes).<sup>31,37</sup></li> <li>• More A1c reduction than most GLP-1 agonists.</li> <li>• No CV or kidney outcomes data yet.</li> <li>• Monitor for retinopathy progression.<sup>31,37</sup></li> <li>• May delay oral contraceptive absorption.<sup>31,37</sup> Advise switching to a non-oral contraceptive or adding a barrier contraceptive for four weeks after initiation or a dosage increase.<sup>31,37</sup></li> </ul>
<b>Insulin:</b> See our chart, Comparison of Insulins (US)(Canada) for available products.			
0.9% to 1.2% or more <sup>1</sup>  MOA: promotes uptake of glucose into muscle and fat tissues; inhibits glucose production. <sup>2</sup>	No maximum dose. <sup>1</sup> See our chart, <i>Comparison of Insulins (US)(Canada)</i> , for cost info.	<ul style="list-style-type: none"> <li>• Hypoglycemia.<sup>4</sup> Educate patient to prevent, recognize, and manage.<sup>1</sup></li> <li>• Highest risk of weight gain (1 to 3.5 kg or more).<sup>1</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Adults: consider initial therapy with insulin if blood glucose is <math>\geq 300</math> mg/dL (<math>\geq 16.7</math> mmol/L) and/or A1c is <math>&gt;10\%</math>.<sup>4</sup></li> <li>• Pediatrics: initial treatment of choice if A1c <math>\geq 8.5\%</math>, or ketoacidosis is present. See <b>footnote d</b>.</li> </ul>
<b>Meglitinide:</b> nateglinide (US) and repaglinide ( <i>GlucoNorm</i> [Canada], generics)			
0.7% to 1.1% <sup>1</sup>  MOA: stimulates pancreatic insulin secretion. <sup>2</sup>	<b>Nateglinide</b> 360 mg, divided TID (US: ~\$67)  <b>Repaglinide</b> 16 mg, divided four times daily (~\$75)(Canada: \$63.24)	<ul style="list-style-type: none"> <li>• Hypoglycemia.<sup>7</sup> Educate patient to prevent, recognize, and manage.<sup>1</sup></li> <li>• Weight gain: 1.4 to 3.3 kg.<sup>1</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Reduces postprandial glucose more than sulfonylureas.<sup>10</sup></li> <li>• Safer than sulfonylureas in kidney impairment.<sup>1</sup></li> <li>• Taken before each meal; hold dose if skipping meal.<sup>2,13</sup></li> <li>• Less hypoglycemia than sulfonylurea.<sup>7</sup></li> </ul>

Expected A1c Reduction <sup>b</sup> /MOA	Maximum Daily Dose <sup>2,24,42</sup> (Cost/30 Days) <sup>a</sup>	Notable Adverse Effects	Comments
<p><b>Sodium-glucose co-transporter 2 (SGLT2) inhibitors:</b></p> <ul style="list-style-type: none"> <li>• bexagliflozin (<i>Brenzavvy</i> [US])</li> <li>• canagliflozin (<i>Invokana</i>; with metformin [<i>Invokamet, Invokamet XR</i>])</li> <li>• dapagliflozin (<i>Farxiga</i> [US]; <i>Forxiga</i>, generics [Canada]; with metformin [<i>Xigduo XR</i>, generics (Canada)]; with saxagliptin [<i>Qtern</i> (US)])</li> <li>• empagliflozin (<i>Jardiance</i>; with linagliptin [<i>Glyxambi</i> (US)]; with metformin [<i>Synjardy, Synjardy XR</i> (US)], with linagliptin and metformin [<i>Trijardy XR</i> (US)])</li> <li>• ertugliflozin (<i>Steglatro</i> [US]; with metformin [<i>Segluromet</i> (US)]; with sitagliptin [<i>Steglujan</i> (US)])</li> </ul>			
<p>0.5% to 0.7% (adults);<sup>1</sup> 0.2% (pediatrics)<sup>43</sup></p> <p>MOA: blocks glucose and sodium reabsorption in the kidney, increases urinary excretion of glucose, sodium, and uric acid, and decrease in plasma volume.<sup>2</sup></p>	<p><b>Bexagliflozin</b> 20 mg once daily (US: \$47.85 [from Cost Plus]<sup>45</sup>)</p> <p><b>Canagliflozin</b> 300 mg once daily (US: \$598.56)(Canada: \$93.67)</p> <p><b>Dapagliflozin</b> 10 mg once daily (US: \$565.29)(Canada: \$22.11)</p> <p><b>Empagliflozin</b> 25 mg once daily (US: \$593.30)(Canada: \$89.65)</p> <p><b>Ertugliflozin</b> 15 mg once daily (US: \$340.80)</p>	<ul style="list-style-type: none"> <li>• Low risk of hypoglycemia when used as monotherapy.<sup>4</sup></li> <li>• Genital fungal (yeast) infections (male/female).<sup>17</sup></li> <li>• UTI (may be severe).<sup>18</sup></li> <li>• Ketoacidosis (rare).<sup>18</sup></li> <li>• Increased urination may lead to volume depletion, hypotension, syncope, falls, and acute kidney injury that may require dialysis.<sup>2</sup></li> <li>• Hyperkalemia (canagliflozin) in kidney impairment, especially with high baseline potassium or use with medications that reduce potassium excretion.<sup>2</sup></li> <li>• Rare reports of acute pancreatitis.<sup>21</sup></li> <li>• Fracture risk (canagliflozin, dapagliflozin; conflicting evidence).<sup>7,41</sup></li> <li>• Fournier’s gangrene (rare; in men and women). Onset: days to years.<sup>17</sup></li> <li>• Amputation risk (canagliflozin; conflicting evidence).<sup>7,41</sup> Consider amputation risk factors (ulcer or amputation history; reduced sensation). Emphasize foot care and monitor for foot/leg pain, tenderness, or sores.<sup>1,19</sup></li> </ul>	<ul style="list-style-type: none"> <li>• First-line for patients with CV disease, high CV risk, heart failure, or CKD.<sup>7</sup> <ul style="list-style-type: none"> <li>○ CV benefit (canagliflozin, dapagliflozin [heart failure], empagliflozin, ertugliflozin heart failure), sotagliflozin).</li> <li>○ Kidney benefit (canagliflozin, dapagliflozin, empagliflozin).</li> </ul> </li> <li>• Add-on to metformin or insulin for patients ≥10 years of age (empagliflozin).<sup>43</sup></li> <li>• Weight loss (2 to 3 kg in adults, 0.79 kg in pediatrics).<sup>1,43</sup></li> <li>• For information on use in kidney impairment, see <b>footnote c</b>.</li> </ul>

Expected A1c Reduction <sup>b</sup> /MOA	Maximum Daily Dose <sup>2,24,42</sup> (Cost/30 Days) <sup>a</sup>	Notable Adverse Effects	Comments
<p><b>Sulfonylurea-second generation</b></p> <ul style="list-style-type: none"> <li>• gliclazide (<i>Diamicon</i> [brand discontinued], generics [Canada]; <i>Diamicon-MR</i>, generics [Canada])</li> <li>• glimepiride (<i>Amaryl</i> [US], generics; with pioglitazone [<i>Duetact</i>, generics (US)]),</li> <li>• glipizide (<i>Glucotrol</i> [brand discontinued], generics (US); <i>Glucotrol XL</i>, generics (US); with metformin [generics (US)])</li> <li>• glyburide (<i>DiaBeta</i> [US], generics; <i>Glynase</i>, generics [US]; with metformin [generics (US)])</li> </ul>			
<p>0.6% to 1.2%<sup>1</sup></p> <p>MOA: stimulates pancreatic insulin secretion.<sup>1</sup></p>	<p><b>Gliclazide</b> (standard) 320 mg (daily doses <math>\geq 160</math> mg should be divided BID)(Canada: \$12.06)</p> <p><b>Gliclazide</b> (modified release) 120 mg once daily (Canada: &lt;\$10)</p> <p><b>Glimepiride</b> 8 mg once daily (US: ~\$15)(Canada: \$67.96)</p> <p><b>Glipizide IR</b> 40 mg (daily doses &gt;30 mg should be divided BID) (US: &lt;\$10)</p> <p><b>Glipizide XL</b> 20 mg once daily (US: ~\$25)</p> <p><b>Glyburide</b> (standard) 20 mg (daily doses &gt;10 mg can be divided BID) (US: ~\$25)(Canada: &lt;\$10)</p> <p><b>Glyburide</b> (micronized) 12 mg (once daily or in divided doses) (US: ~\$20)</p>	<ul style="list-style-type: none"> <li>• Hypoglycemia, especially with glyburide and/or in kidney impairment.<sup>1</sup> Educate patient to prevent, recognize, and manage.<sup>1</sup> <ul style="list-style-type: none"> <li>○ Hypoglycemic risk with glipizide or gliclazide &lt; glimepiride &lt; glyburide.<sup>13,22</sup></li> </ul> </li> <li>• Weight gain: 1.2 to 3.2 kg.<sup>1</sup> <ul style="list-style-type: none"> <li>○ Less weight gain with glipizide and glimepiride versus glyburide.<sup>23</sup></li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Sulfonylureas lack cardiovascular benefit.<sup>22</sup></li> <li>• Efficacy is relatively short-lived.<sup>1</sup></li> <li>• Consider for glycemic control in patients for whom cost is a barrier to treatment.<sup>7</sup></li> <li>• Discontinue when more complex insulin regimens (e.g., basal plus prandial insulins) are started.<sup>4</sup></li> <li>• Avoid sulfonylureas in the elderly, in patients with hypoglycemia risk, and in patients who are overweight or obese.<sup>7,22</sup></li> <li>• Not preferred in youth due to weight gain and hypoglycemia (requires self-monitoring of blood glucose), and potential for accelerated loss of beta-cell function.<sup>27</sup></li> <li>• Avoid glyburide in kidney impairment.<sup>1,4</sup></li> <li>• Start low and titrate. Periodically consider need for dose reduction as the patient ages and circumstances change (e.g., reduced oral intake, kidney impairment).<sup>25</sup></li> </ul>



Expected A1c Reduction <sup>b</sup> /MOA	Maximum Daily Dose <sup>2,24,42</sup> (Cost/30 Days) <sup>a</sup>	Notable Adverse Effects	Comments
<b>Thiazolidinedione (TZD):</b> pioglitazone ( <i>Actos</i> [US], generics; with metformin [ <i>ACTOplus Met</i> , generics (US)]; with glimepiride [ <i>Duetact</i> , generics (US)], with alogliptin [ <i>Oseni</i> , authorized generics])			
0.7% to 0.9% <sup>1</sup> MOA: increases insulin sensitivity in liver, muscle, and fat. <sup>2</sup>	<b>Pioglitazone</b> 45 mg once daily (US: ~\$10)(Canada: \$31.72)	<ul style="list-style-type: none"> <li>• Low risk of hypoglycemia when used as monotherapy.<sup>4</sup></li> <li>• Edema.<sup>1</sup></li> <li>• Weight gain: 2 to 2.5 kg or more.<sup>1</sup></li> <li>• Heart failure.<sup>1</sup> Avoid in patients with symptomatic heart failure.<sup>7</sup></li> <li>• Increased fracture risk.<sup>1</sup></li> <li>• Do not use in active bladder cancer, and use caution in patients with a history of bladder cancer.<sup>2</sup> Counsel patients to report hematuria or increased or painful urination.<sup>2</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Reduces risk of recurrent stroke.<sup>7</sup></li> <li>• Beneficial in the treatment of prediabetes.<sup>7</sup></li> <li>• Lowers triglycerides.<sup>7</sup></li> <li>• Glycemic control is better sustained over diabetes course than metformin or sulfonylureas.<sup>13</sup></li> <li>• Not preferred in youth due to weight gain (especially with insulin). Could consider if metformin is not tolerated and cardiac function is normal, given that youth have tend to have severe insulin resistance. Consider a max dose of 30 mg/day (45 mg dose has limited additional benefit with more side effects).<sup>27</sup></li> </ul>
<b>Others – bile acid sequestrant:</b> colestevlam ( <i>Welchol</i> , generics [US])			
0.5% <sup>28</sup> MOA: may reduce liver glucose production, increase GLP-1 levels, and decrease glucose absorption. <sup>28,29</sup>	<b>Colestevlam</b> 3.75 gm, given once daily or divided BID (US: ~\$350 [powder for suspension]; ~\$120 [tablets])	<ul style="list-style-type: none"> <li>• Low incidence of mild to moderate hypoglycemia.<sup>28</sup></li> <li>• GI (e.g., constipation, nausea, dyspepsia).<sup>28</sup></li> <li>• May increase triglycerides.<sup>28</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Diabetes is not a Health Canada-approved indication.<sup>26</sup></li> <li>• Weight neutral.<sup>7</sup></li> <li>• Lowers LDL cholesterol.<sup>28</sup></li> <li>• May decrease absorption of other meds.<sup>2</sup></li> </ul>
<b>Others – dopamine agonist:</b> bromocriptine ( <i>Cycloset</i> [US])			
0.5% (when added to metformin and a sulfonylurea) <sup>30</sup> MOA: increases insulin sensitivity. <sup>30</sup>	<b>Bromocriptine</b> 4.8 mg once daily (~\$999.58)	<ul style="list-style-type: none"> <li>• Infrequent hypoglycemia.<sup>2,30</sup></li> <li>• Nausea, rhinitis, headache.<sup>30</sup></li> <li>• Orthostasis (may include nausea and sweating as well as dizziness).<sup>30</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Weight neutral.<sup>7</sup></li> <li>• Avoid with strong CYP3A4 inhibitors.<sup>30</sup></li> <li>• May worsen psychosis.<sup>30</sup></li> <li>• Take within 2 hours of awakening, with food.<sup>2</sup></li> </ul>

a. Unless otherwise specified, pricing (for generic when available) is based on wholesale acquisition cost (WAC). US medication pricing by Elsevier, accessed July 2023. Canadian price is wholesale.

- b. As a metformin add-on, unless otherwise noted.
- c. Use of SGLT2 antagonists in kidney impairment:
- **Bexagliflozin:** not recommended if eGFR <30 mL/min/1.73m<sup>2</sup>.<sup>46</sup>
  - **Canagliflozin:** do not **initiate** if eGFR <20 mL/min/1.73m<sup>2</sup>.<sup>2</sup> Reduce dose to 100 mg/day in patients with eGFR <60 mL/min/1.73m<sup>2</sup>.<sup>2</sup> Limited efficacy for **glycemic control** if eGFR <30 mL/min/1.73m<sup>2</sup>, but can **continue** for CV or kidney indications until dialysis is needed.<sup>2</sup>
  - **Dapagliflozin:** do not **initiate** if eGFR <25 mL/min/1.73m<sup>2</sup>.<sup>2</sup> Limited efficacy for **glycemic control** if eGFR <45 mL/min/1.73m<sup>2</sup>, but can **continue** for CV or kidney indications until dialysis is needed.<sup>2</sup>
  - **Empagliflozin:** do not **initiate** if eGFR <20 mL/min/1.73m<sup>2</sup>.<sup>2</sup> Reduce dose to 10 mg/day in patients with eGFR <30 mL/min/1.73m<sup>2</sup> (US).<sup>2</sup> Limited efficacy for **glycemic control** if eGFR <30 mL/min/1.73m<sup>2</sup>, but can **continue** for CV or kidney indications until dialysis is needed.<sup>2</sup> (Canada: empagliflozin contraindicated for glycemic control if eGFR <20 mL/min/1.73m<sup>2</sup>.<sup>39</sup>).
  - **Ertugliflozin:** limited efficacy for **glycemic control** if eGFR <45 mL/min/1.73m<sup>2</sup>, but can **continue** for CV or kidney indications until dialysis is needed.<sup>2</sup>
- d. **Insulin** use in **pediatrics:** Start basal insulin at 0.25 to 0.5 units/kg. Attempt transition to metformin over two to six weeks (once labs have stabilized), by decreasing insulin each time metformin is increased.<sup>27</sup> Offer continuous glucose monitoring to youth receiving multiple daily injections or continuous subcutaneous insulin infusion.<sup>20</sup>

**Abbreviations:** BID = two times daily; BMD = bone mineral density; CKD = chronic kidney disease; CV = cardiovascular; eGFR = estimated glomerular filtration rate; GI = gastrointestinal; LDL = low-density lipoprotein; MOA = mechanism of action; TID = three times daily; UTI = urinary tract infection.



*Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.*

## References

1. Diabetes Canada Clinical Practice Guidelines Expert Committee, Lipscombe L, Butalia S, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. *Can J Diabetes*. 2020 Oct;44(7):575-591.
2. Clinical Pharmacology powered by ClinicalKey. Tampa (FL): Elsevier. 2023. <http://www.clinicalkey.com>. (Accessed July 16, 2023).
3. Product information for miglitol. Westminster Pharmaceuticals. Nashville, TN 37217. October 2020.
4. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. *Diabetes Care*. 2023 Jan 1;46(Suppl 1):S140-S157.
5. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet*. 2002 Jun 15;359(9323):2072-7.
6. DiNicolantonio JJ, Bhutani J, O'Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. *Open Heart*. 2015 Oct 19;2(1):e000327.
7. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. *Erratum In: Endocr Pract*. 2023 May;29(5):305-340.
8. Pullman J, Darsow T, Frias JP. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. *Vasc Health Risk Manag*. 2006;2(3):203-12.
9. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Metformin Use in Patients with Historical Contraindications or Precautions [Internet]. Washington (DC): Department of Veterans Affairs (US); 2016 Sep.
10. Diabetes Canada Clinical Practice Guidelines Expert Committee, Lipscombe L, Booth G, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. *Can J Diabetes*. 2018 Apr;42 Suppl 1:S88-S103. *Erratum in: Can J Diabetes*. 2018 Jun;42(3):336. *Erratum in: Can J Diabetes*. 2018 Oct;42(5):575.
11. Drugs in liver cirrhosis. Metformin. <http://drugsinlivercirrhosis.org/healthcare-professionals/drugs/metformin/>. (Accessed July 18, 2023).
12. FDA. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Content current as of November 14, 2017. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain>. (Accessed July 18, 2023).
13. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Harper W, Clement M, et al. Pharmacologic management of type 2 diabetes. *Can J Diabetes*. 2013 Apr;37 Suppl 1:S61-8.
14. Gallwitz B. Clinical Use of DPP-4 Inhibitors. *Front Endocrinol (Lausanne)*. 2019 Jun 19;10:389. doi: 10.3389/fendo.2019.00389.
15. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. *N Engl J Med*. 2014 Feb 27;370(9):794-7. *Erratum in: N Engl J Med*. 2014 Jun 5;370(23):2253.
16. Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. *J Clin Pharm Ther*. 2020 Sep;45 Suppl 1(Suppl 1):43-60.
17. FDA. Drug safety communication. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. September 7, 2018. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sgl2-inhibitors-diabetes>. (Accessed July 19, 2023).
18. FDA. Drug safety communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infection. March 16, 2022. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sgl2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious>. (Accessed July 19, 2023).
19. FDA. Drug safety communication. FDA removes Boxed Warning about risk of leg and foot amputation for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) based on our review of new clinical trial data. September 2, 2020. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin>. (Accessed July 19, 2023).
20. ElSayed NA, Aleppo G, Aroda VR, et al. 7. Diabetes Technology: Standards of Care in Diabetes-2023. *Diabetes Care*. 2023 Jan 1;46(Suppl 1):S111-S127.
21. Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. *BMJ*. 2018 Nov 14;363:k4365. doi: 10.1136/bmj.k4365.
22. By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. *J Am Geriatr Soc*. 2023 Jul;71(7):2052-2081.
23. Malone M. Medications associated with weight gain. *Ann Pharmacother*. 2005 Dec;39(12):2046-55.
24. Product monograph for *Diamicron MR*. Servier Canada. Laval, QC H7V 4A7. September 2019.

25. NHS. Wessex Academic Science Network. Medicine safety portal: safe prescribing for primary care. Sulfonylureas: protecting patients from hypoglycaemia. <https://www.medicinesafety.co.uk/2020/02/sulfonylureas-protecting-patients.html>. (Accessed July 20, 2023).
26. Product monograph for Lodalis. Bausch Health Canada. Laval, QC H7L 4A8. December 2020.
27. Shah AS, Zeitler PS, Wong J, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents. *Pediatr Diabetes*. 2022 Nov;23(7):872-902.
28. Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2012 Dec 12;12(12):CD009361.
29. Patel PH, Can AS. Colesevelam. 2023 May 1. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. PMID: 32491747.
30. Product information for Cycloset. Salix Pharmaceuticals. Bridgewater, NJ 08807. August 2020.
31. Product information for Mounjaro. Eli Lilly USA. Indianapolis, IN 46285. May 2023.
32. Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. *Ther Adv Endocrinol Metab*. 2021 Mar 9;12:2042018821997320.
33. Product information for Trulicity. Eli Lilly. Indianapolis, IN 46285. December 2022.
34. Product information for Bydureon BCise. AstraZeneca Pharmaceuticals Wilmington, DE 19850. May 2023.
35. Tamborlane WV, Bishai R, Geller D, et al. Once-Weekly Exenatide in Youth With Type 2 Diabetes. *Diabetes Care*. 2022 Aug 1;45(8):1833-1840.
36. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in Children and Adolescents with Type 2 Diabetes. *N Engl J Med*. 2019 Aug 15;381(7):637-646.
37. Product monograph for Mounjaro. Eli Lilly Canada. Toronto, ON M5X 1B1. November 2022.
38. Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. *Lancet Diabetes Endocrinol*. 2021 Sep;9(9):563-574.
39. Product monograph. Jardiance. Boehringer Ingelheim. Burlington, ON L7L 5H4. May 2023.
40. Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. *Drug Des Devel Ther*. 2009 Feb 6;2:203-14.
41. Mascolo A, Di Napoli R, Balzano N, et al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. *Front Cardiovasc Med*. 2022 Sep 21;9:1010693.
42. Product monograph for Teva-gliclazide. December 2019.
43. Laffel LM, Danne T, Klingensmith GJ, et al. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. *Lancet Diabetes Endocrinol*. 2023 Mar;11(3):169-181.
44. EISayed NA, Aleppo G, Aroda VR, et al. 14. Children and Adolescents: Standards of Care in Diabetes-2023. *Diabetes Care*. 2023 Jan 1;46(Suppl 1):S230-S253.
45. Briskin A, Chen S. Brenzavvy, a type 2 diabetes drug, now available for less than \$50 month. July 14, 2023. <https://diatribe.org/brenzavvy-type-2-diabetes-drug-now-available-less-50-month>. (Accessed July 27, 2023).
46. Product monograph for *Brenzavvy*. TheracosBio. Marlborough, MA 01752. July 2023.

***Cite this document as follows: Clinical Resource, Drugs for Type 2 Diabetes. Pharmacist's Letter/Pharmacy Technician's Letter/Prescriber Insights. August 2023. [390803]***

—To access hundreds more clinical resources like this one, visit [trchealthcare.com](https://trchealthcare.com) to log in or subscribe—